A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872
Journal article published in 2019 by
Evanthia Galanis 
,
S. Keith Anderson,
Erin L. Twohy,
Xiomara W. Carrero,
Jesse G. Dixon,
David Dinh Tran,
Suriya A. Jeyapalan,
Daniel M. Anderson,
Timothy J. Kaufmann,
Ryan W. Feathers,
Caterina Giannini,
Jan C. Buckner,
Panos Z. Anastasiadis,
David Schiff
,
S. Keith Anderson,
Erin L. Twohy,
Xiomara W. Carrero,
Jesse G. Dixon,
David Dinh Tran,
Suriya A. Jeyapalan,
Daniel M. Anderson,
Timothy J. Kaufmann,
Ryan W. Feathers,
Caterina Giannini,
Jan C. Buckner,
Panos Z. Anastasiadis,
David Schiff
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 